This study focuses on the management of patients with mCRC, but KRAS, NRAS or BRAF mutations testing is also relevant in other cancers like metastatic melanoma or non-small cell lung cancer [16,17]. This evidence concerns the gene NRAS and non-small cell lung carcinoma.